Disclosed are Fe(III) complexes with bidentate pyrimidine ligands (formula I) and pharmaceutical compositions for use in the treatment and prevention of iron dificency and anaema. In comparison to classical preparations of Fe(II) salts, the complexes have fewer side effects, lower toxicity, low molecular weight, high complex stability and do not lead to free Fe which catalyses the formation of reactive oxygen species that cause oxidative stress.